NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: COHANCE · data 2026-10-31
Cohance Lifesciences Ltd
In plain words
Price: 41.6% below its 52-week high of ₹760.8.
Delivery: 47.1% of traded shares were kept for delivery over the last 10 sessions, against 45.6% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,142 cr |
| Net profit (last 12 months) | ₹106 cr |
| Sales growth, 3 years (yearly) | 19.0% |
| Profit growth, 3 years (yearly) | -24.2% |
At a glance
Promoters 57.5% (unchanged in a year), pledged 94.6%, institutions 26.6%.
P/E 161.0, P/B 4.4, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 6.4%, ROCE 4.6%, operating margin 5.8%: how much profit it earns on the money it uses.
Debt/equity 0.10, Profit growth -24.2% and sales growth 19.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Low return on equity (6.4%).
- Profit fell 24.2% a year over 3 years.
- Promoters have pledged 94.6% of their shares.
- Expensive on earnings (P/E 161.0).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
27/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 7/30: Delivery 42.5% over the last 20 sessions vs 35.9% in the 40 before (1.18x); shares delivered per day 0.68x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 6 schemes hold it, about ₹473 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 55/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 57.48% | 57.49% | 57.49% | 57.49% |
| Foreign institutions (FII) | 7.71% | 6.50% | 5.59% | 6.02% |
| Domestic institutions (DII) | 18.86% | 20.09% | 21.79% | 21.57% |
| Mutual funds | 16.93% | 18.21% | 18.57% | 17.36% |
| Retail investors | 7.25% | 7.39% | 6.85% | 6.50% |
| Number of shareholders | 93,846 | 99,149 | 85,230 | 81,877 |
Common questions
How much do promoters hold in Cohance Lifesciences Ltd?
Promoters held 57.48% of Cohance Lifesciences Ltd at the end of Sept 2026, with 94.56% of promoter shares pledged.
Is Cohance Lifesciences Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.1.
What is Cohance Lifesciences Ltd's P/E ratio?
About 161, based on the last 12 months' earnings and a price of ₹444.3 (data 2026-10-31).
What is the 52-week high and low of Cohance Lifesciences Ltd?
The 52-week high is ₹760.8 and the 52-week low is ₹266.7.
Mutual funds holding Cohance Lifesciences Ltd
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 6 schemes holding about ₹473 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Multi Asset Allocation Fund | SBI Mutual Fund | 1.10% | ₹232 cr |
| SBI MNC Fund | SBI Mutual Fund | 1.53% | ₹98 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 1.66% | ₹97 cr |
| ADITYA BIRLA SUN LIFE MNC FUND | Aditya Birla Sun Life Mutual Fund | 0.81% | ₹25 cr |
| SBI Balanced Hybrid Fund | SBI Mutual Fund | 1.12% | ₹22 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.54% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Cohance Lifesciences Ltd | ₹444.3 | ₹17,005 cr | 161 | 4.4 | 6.4% | 4.6% | 0.1 | -44.0% |
| OneSource Specialty Pharma Limited | ₹1,563 | ₹17,926 cr | — | 3 | -1.3% | -0.1% | 0.26 | -15.1% |
| Caplin Point Laboratories Limited | ₹2,325.6 | ₹17,672 cr | 26.7 | — | 19.9% | 20.9% | 0 | +15.2% |
| Alivus Life Sciences Ltd | ₹1,415.3 | ₹17,284 cr | 26 | 4.8 | 18.4% | 22.4% | 0.02 | +55.2% |
| PFIZER LIMITED | ₹3,687.8 | ₹16,867 cr | 23 | — | 17.2% | 20% | 0.02 | -30.0% |
| Eris Lifesciences Ltd | ₹1,156.4 | ₹16,088 cr | 22.5 | 3.9 | 18.3% | 15.6% | 0.6 | -29.0% |
Compare COHANCE with ONESOURCE in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open COHANCE in NSE Scanner →